94 related articles for article (PubMed ID: 17211992)
1. Targeting human immunodeficiency virus type 1 with antibodies derived from patients with connective tissue disease.
Scherl M; Posch U; Obermoser G; Ammann C; Sepp N; Ulmer H; Dierich MP; Stoiber H; Falkensammer B
Lupus; 2006; 15(12):865-72. PubMed ID: 17211992
[TBL] [Abstract][Full Text] [Related]
2. Complement-mediated enhancement of HIV-1 neutralisation by anti-HLA antibodies derived from polytransfused patients.
Wilfingseder D; Spruth M; Ammann CG; Döpper S; Speth C; Dierich MP; Stoiber H
Int Arch Allergy Immunol; 2003 May; 131(1):62-72. PubMed ID: 12759492
[TBL] [Abstract][Full Text] [Related]
3. Binding of glycoprotein 120 and peptides from the HIV-1 envelope by autoantibodies in mice with experimentally induced systemic lupus erythematosus and in patients with the disease.
Bermas BL; Petri M; Berzofsky JA; Waisman A; Shearer GM; Mozes E
AIDS Res Hum Retroviruses; 1994 Sep; 10(9):1071-7. PubMed ID: 7826694
[TBL] [Abstract][Full Text] [Related]
4. Panel of anti-gp120 monoclonal antibodies reacts with same nuclear proteins in uninfected cells as those recognized by autoantibodies from patients with systemic lupus erythematosus.
Pinto LA; Dalgleish AG; Sumar N; Poulton TA
AIDS Res Hum Retroviruses; 1994 Jul; 10(7):823-8. PubMed ID: 7986588
[TBL] [Abstract][Full Text] [Related]
5. Cross-reactivity between autoimmune anti-U1 snRNP antibodies and neutralizing epitopes of HIV-1 gp120/41.
Douvas A; Takehana Y
AIDS Res Hum Retroviruses; 1994 Mar; 10(3):253-62. PubMed ID: 7517148
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of soluble CD4-mediated HIV neutralization and gp 120 binding by CD4 autoantibodies and monoclonal antibodies.
Moore JP; Sattentau QJ; Clapham PR
AIDS Res Hum Retroviruses; 1990 Nov; 6(11):1273-9. PubMed ID: 2078408
[TBL] [Abstract][Full Text] [Related]
7. Neutralization of HIV type 1 by alloimmune sera derived from polytransfused patients.
Spruth M; Stoiber H; Kacani L; Schönitzer D; Dierich MP
AIDS Res Hum Retroviruses; 1999 Apr; 15(6):533-43. PubMed ID: 10221530
[TBL] [Abstract][Full Text] [Related]
8. Complement-activating antibodies in sera from infected individuals and vaccinated volunteers that target human immunodeficiency virus type 1 to complement receptor type 1 (CR1, CD35).
Zhou J; Montefiori DC
Virology; 1996 Dec; 226(1):13-21. PubMed ID: 8941318
[TBL] [Abstract][Full Text] [Related]
9. Neutralization of HIV type 1 infectivity by serum antibodies from a subset of autoimmune patients with mixed connective tissue disease.
Douvas A; Takehana Y; Ehresmann G; Chernyovskiy T; Daar ES
AIDS Res Hum Retroviruses; 1996 Nov; 12(16):1509-17. PubMed ID: 8911576
[TBL] [Abstract][Full Text] [Related]
10. Epitope specificity of anti-HIV antibodies in human and murine autoimmune diseases.
Fraziano M; Montesano C; Lombardi VR; Sammarco I; De Pisa F; Mattei M; Valesini G; Pittoni V; Colizzi V
AIDS Res Hum Retroviruses; 1996 Apr; 12(6):491-6. PubMed ID: 8679304
[TBL] [Abstract][Full Text] [Related]
11. Tumour necrosis factor-alpha increases the sensitivity of human immunodeficiency virus (HIV)-infected monocytic U937 cells to the complement-dependent cytotoxicity of sera from HIV type 1-infected individuals; role of the gp120 protein.
Szabò B; Locardi C; Lo Presti E; Belardelli F; Benedetto A
J Gen Virol; 1993 Jul; 74 ( Pt 7)():1271-6. PubMed ID: 8336118
[TBL] [Abstract][Full Text] [Related]
12. High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas.
Carrow EW; Vujcic LK; Glass WL; Seamon KB; Rastogi SC; Hendry RM; Boulos R; Nzila N; Quinnan GV
AIDS Res Hum Retroviruses; 1991 Oct; 7(10):831-8. PubMed ID: 1720630
[TBL] [Abstract][Full Text] [Related]
13. Improbability of harmful autoimmune responses resulting from immunization with HIV-1 envelope glycoproteins.
Neurath AR; Strick N; Li YY; Jiang S
AIDS Res Hum Retroviruses; 1993 Dec; 9(12):1195-208. PubMed ID: 8142138
[TBL] [Abstract][Full Text] [Related]
14. Characterization of a mouse/human chimeric monoclonal antibody (C beta 1) to a principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.
Matsushita S; Maeda H; Kimachi K; Eda Y; Maeda Y; Murakami T; Tokiyoshi S; Takatsuki K
AIDS Res Hum Retroviruses; 1992 Jun; 8(6):1107-15. PubMed ID: 1380258
[TBL] [Abstract][Full Text] [Related]
15. Autoantibodies directed against CD43 molecules with an altered glycosylation status on human immunodeficiency virus type 1 (HIV-1)-infected CEM cells are found in all HIV-1+ individuals.
Giordanengo V; Limouse M; Desroys du Roure L; Cottalorda J; Doglio A; Passeron A; Fuzibet JG; Lefebvre JC
Blood; 1995 Sep; 86(6):2302-11. PubMed ID: 7662977
[TBL] [Abstract][Full Text] [Related]
16. The role of complement and gp120-specific antibodies in virus lysis and CD4+ T cell depletion in HIV-1-infected patients.
Gerencer M; Burek V; Crowe BA; Barrett NP; Dorner F
Microb Pathog; 1998 Nov; 25(5):253-66. PubMed ID: 9878454
[TBL] [Abstract][Full Text] [Related]
17. Antibodies reactive with HIV-1 antigens in systemic lupus erythematosus.
Gül A; Inanç M; Yilmaz G; Ocal L; Koniçe M; Aral O; Badur S; Dilşen N
Lupus; 1996 Apr; 5(2):120-2. PubMed ID: 8743124
[TBL] [Abstract][Full Text] [Related]
18. Autoantibodies to phospholipids and to the coagulation proteins in AIDS.
Abuaf N; Laperche S; Rajoely B; Carsique R; Deschamps A; Rouquette AM; Barthet C; Khaled Z; Marbot C; Saab N; Rozen J; Girard PM; Rozenbaum W
Thromb Haemost; 1997 May; 77(5):856-61. PubMed ID: 9184392
[TBL] [Abstract][Full Text] [Related]
19. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region.
Barnett SW; Lu S; Srivastava I; Cherpelis S; Gettie A; Blanchard J; Wang S; Mboudjeka I; Leung L; Lian Y; Fong A; Buckner C; Ly A; Hilt S; Ulmer J; Wild CT; Mascola JR; Stamatatos L
J Virol; 2001 Jun; 75(12):5526-40. PubMed ID: 11356960
[TBL] [Abstract][Full Text] [Related]
20. Autoantibodies to DNA topoisomerase II in cryptogenic fibrosing alveolitis and connective tissue disease.
Meliconi R; Bestagno M; Sturani C; Negri C; Galavotti V; Sala C; Facchini A; Ciarrocchi G; Gasbarrini G; Astaldi Ricotti GC
Clin Exp Immunol; 1989 May; 76(2):184-9. PubMed ID: 2547538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
